Chabon and colleagues profiled ctDNA in 100 early-stage NSCLC patients, achieving over 85% sensitivity in detecting key mutations and demonstrating reduced immunotherapy responses in patients with KEAP1/STK11 co-mutations [72]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.